IDI Farmaceutici Partners with SPA for Growth
Deal News | Nov 15, 2024 | Legal Community Italy
In a significant transaction finalized in Milan, the Fondazione Luigi Maria Monti, owner of the renowned Ospedale IDI IRCCS, has sold a 40% minority stake in IDI Farmaceutici S.r.l. to SPA Società Prodotti Antibiotici S.p.A. This strategic partnership between historic Italian pharmaceutical brands aims to leverage their complementary strengths for commercial and industrial synergy. This deal is a key step in the asset strengthening and repositioning strategy initiated by the Fondazione Luigi Maria Monti in 2022. The transaction saw the involvement of various legal and financial advisors, ensuring smooth execution. Dr. Eugenio Favale played a pivotal role as the financial advisor. Legal and corporate M&A aspects were covered by Professor Domenico Giampetruzzi from Schiano&Partners, while financial matters saw the involvement of Dr. Maurizio Bernardo from e-IUS Tax & Legal. SPA was supported by Greenberg Traurig Santa Maria, with their team handling both legal and financial details. PwC TLS assisted the Fondazione Luigi Maria Monti with their creditor agreements as outlined in the industrial plan approved by the Rome Tribunal. Lastly, LMS Studio Legale supported Altea SPV, managed by Prelios, acting as a financial creditor in this transaction.
Sectors
- Pharmaceuticals
- Legal Services
Geography
- Italy – Both companies involved in the transaction are historic Italian pharmaceutical brands and the deal was finalized in Milan.
Industry
- Pharmaceuticals – The transaction involves IDI Farmaceutici and SPA, both of which are established players in the pharmaceutical industry.
- Legal Services – Multiple legal advisory firms participated in the transaction, providing M&A and financial advisory services.
Financials
- 40% – The percentage stake in IDI Farmaceutici acquired by SPA.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Fondazione Luigi Maria Monti | Vendor | Company | A foundation operating the renowned Ospedale IDI IRCCS, which sold a minority stake in IDI Farmaceutici. |
| IDI Farmaceutici S.r.l. | Target Company | Company | A historic Italian pharmaceutical company that is partly owned by Fondazione Luigi Maria Monti. |
| SPA Società Prodotti Antibiotici S.p.A. | Buyer | Company | An Italian pharmaceutical company acquiring a 40% stake in IDI Farmaceutici. |
| Dr. Eugenio Favale | Financial Advisor | Person | The financial advisor overseeing the transaction. |
| Professor Domenico Giampetruzzi | Legal Advisor | Person | Provided legal and corporate M&A advice through Schiano & Partners. |
| Schiano & Partners | Legal Firm | Company | Legal advisors to Fondazione Luigi Maria Monti and IDI Farmaceutici for M&A. |
| Dr. Maurizio Bernardo | Financial Advisor | Person | Provided financial advice through e-IUS Tax & Legal. |
| e-IUS Tax & Legal | Financial Advisory Firm | Company | Advisors on financial matters concerning the transaction. |
| Greenberg Traurig Santa Maria | Legal Firm | Company | Legal advisors to SPA in the transaction. |
| PwC TLS | Advisory Firm | Company | Assisted the Fondazione Luigi Maria Monti in financial restructuring. |
| LMS Studio Legale | Legal Firm | Company | Legal advisors to Altea SPV. |
| Prelios | Asset Management | Company | Manager of Altea SPV, a financial creditor of Fondazione Luigi Maria Monti. |